/index.php?option=com_iwpfile&file=/dir_01/he2002_2960.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2959.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2958.pdf


For Immediate Release

Office of the Press Secretary

November 29, 2002

World AIDS Day, 2002

By the President of the United States of America

A Proclamation

The HIV/AIDS pandemic has taken the lives of more than 20 million people and is projected to take millions more. On World AIDS Day, countries around the world are united to support the individuals, families, and communities affected by this disease, and to renew our commitment to preventing the spread of HIV/AIDS, developing and delivering more effective treatments, and finding a cure.



ed

NATIONAL INSTITUTES OF HEALTH

National Institute of Child Health and Human Development

NIH NEWS RELEASE

EMBARGOED FOR RELEASE

Friday, November 29, 2002

12:01 a.m. ET

Contact: Robert Bock or Marianne Glass Duffy

(301) 496-5133

STUDY CONFIRMS BREAST CANCER RISK IN CONTINUOUS COMBINED HORMONE THERAPY RISK BEGINS TO RETURN TO NORMAL AFTER WOMEN STOP TAKING HORMONES



FDA Talk Papers are prepared by the Press Office to guide FDA personnel in responding with consistency and accuracy to questions from the public on subjects of current interest. Talk Papers are subject to change as more information becomes available.

T02-50

Media Inquiries: 301-827-6242

November 26, 2002

Consumer Inquiries: 888-INFO-FDA





rs

From: News, FDA

Sent: Wednesday, November 27, 2002 11:50 AM

To: FDA-Wide Metro

Subject: Appointment of Assistant Commissioner for Regulatory Affairs



FOR IMMEDIATE RELEASE

P02-51

November 27, 2002

Media Inquiries: 301-827-6242

Consumer Inquiries: 888-INFO-FDA

FDA has approved Claritin (loratadine) as an over-the-counter (OTC) allergy drug product. Previously available only as a prescription drug, Claritin is approved for seasonal allergic rhinitis -- a condition that causes runny nose, nasal congestion, sneezing, and itchy nose, throat, eyes, and ears.



FOR IMMEDIATE RELEASE

CONTACT: Sherrie Borden

301/816-8268; slb@usp.org



Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.